Your browser doesn't support javascript.
loading
Revealing the impact of structural variants in multiple myeloma.
Rustad, Even H; Yellapantula, Venkata D; Glodzik, Dominik; Maclachlan, Kylee H; Diamond, Benjamin; Boyle, Eileen M; Ashby, Cody; Blaney, Patrick; Gundem, Gunes; Hultcrantz, Malin; Leongamornlert, Daniel; Angelopoulos, Nicos; Agnelli, Luca; Auclair, Daniel; Zhang, Yanming; Dogan, Ahmet; Bolli, Niccolò; Papaemmanuil, Elli; Anderson, Kenneth C; Moreau, Philippe; Avet-Loiseau, Hervé; Munshi, Nikhil C; Keats, Jonathan J; Campbell, Peter J; Morgan, Gareth J; Landgren, Ola; Maura, Francesco.
Afiliación
  • Rustad EH; Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Yellapantula VD; Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Glodzik D; Epidemiology & Biostatistics, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Maclachlan KH; Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Diamond B; Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Boyle EM; NYU Perlmutter Cancer Center, New York, New York.
  • Ashby C; Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, Arkansas.
  • Blaney P; NYU Perlmutter Cancer Center, New York, New York.
  • Gundem G; Epidemiology & Biostatistics, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Hultcrantz M; Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Leongamornlert D; The Cancer, Ageing and Somatic Mutation Programme, Wellcome Sanger Institute, Hinxton, Cambridgeshire, United Kingdom.
  • Angelopoulos N; The Cancer, Ageing and Somatic Mutation Programme, Wellcome Sanger Institute, Hinxton, Cambridgeshire, United Kingdom.
  • Agnelli L; School of Computer Science and Electronic Engineering, University of Essex, Colchester, United Kingdom.
  • Auclair D; Department of Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Zhang Y; Multiple Myeloma Research Foundation (MMRF), Norwalk, Connecticut.
  • Dogan A; Cytogenetics Laboratory, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Bolli N; Hematopathology Service, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Papaemmanuil E; Department of Oncology and Hematology-Oncology, University of Milan, Milan, Italy.
  • Anderson KC; Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Moreau P; Epidemiology & Biostatistics, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Avet-Loiseau H; Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Munshi NC; CRCINA, INSERM, CNRS, Université d'Angers, Université de Nantes, Nantes, France.
  • Keats JJ; IUC-Oncopole, and CRCT INSERM U1037, Toulouse, France.
  • Campbell PJ; Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Morgan GJ; Veterans Administration Boston Healthcare System, West Roxbury, Massachusetts.
  • Landgren O; Translational Genomics Research Institute (TGen), Phoenix, Arizona.
  • Maura F; The Cancer, Ageing and Somatic Mutation Programme, Wellcome Sanger Institute, Hinxton, Cambridgeshire, United Kingdom.
Blood Cancer Discov ; 1(3): 258-273, 2020 11.
Article en En | MEDLINE | ID: mdl-33392515
The landscape of structural variants (SVs) in multiple myeloma remains poorly understood. Here, we performed comprehensive analysis of SVs in a large cohort of 752 multiple myeloma patients by low coverage long-insert whole genome sequencing. We identified 68 SV hotspots involving 17 new candidate driver genes, including the therapeutic targets BCMA (TNFRSF17), SLAMF and MCL1. Catastrophic complex rearrangements termed chromothripsis were present in 24% of patients and independently associated with poor clinical outcomes. Templated insertions were the second most frequent complex event (19%), mostly involved in super-enhancer hijacking and activation of oncogenes such as CCND1 and MYC. Importantly, in 31% of patients two or more seemingly independent putative driver events were caused by a single structural event, demonstrating that the complex genomic landscape of multiple myeloma can be acquired through few key events during tumor evolutionary history. Overall, this study reveals the critical role of SVs in multiple myeloma pathogenesis.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Cromotripsis / Secuenciación Completa del Genoma / Mieloma Múltiple Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Blood Cancer Discov Año: 2020 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Cromotripsis / Secuenciación Completa del Genoma / Mieloma Múltiple Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Blood Cancer Discov Año: 2020 Tipo del documento: Article
...